Αποτελέσματα Αναζήτησης
1 Μαΐ 2018 · Dose-Dense AC (DD-AC, Doxorubicin + Cyclophosphamide) + TH (Taxol® + Herceptin®) is a Chemotherapy Regimen for Breast Cancer - early stage. How does Dose-Dense AC + TH work? Doxorubicin, cyclophosphamide, and paclitaxel are designed to kill or slow the growth of cancer cells.
1 Μαρ 2006 · Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance.
25 Μαΐ 2023 · Chemotherapy success rates and cancer survival rates can vary. This article outlines the use of chemotherapy drugs in the treatment of different cancers. We describe how many people with...
We examined temporal trends and clinical associations with ACT vs. TC use in clinical practice in older women and compared the overall survival of patients receiving adjuvant ACT vs. TC. Methods: We used the SEER-Medicare database for women over 65 diagnosed 2004-2009. Women were classified by regimen received: ACT, TC, and other (including ...
23 Ιουν 2022 · Testicular cancer survival has increased from 83% in patients who were diagnosed during the mid-1970s to 95% in the most recent time period, largely because of the success of chemotherapy regimens for advanced disease.
30 Νοε 2020 · In this PSM registry analysis of surgically treated female patients aged 70 years and older with TNBC without distant metastasis, we identified a significant benefit both in 5-year BCSS and 5-year OS with adjuvant chemotherapy versus no chemotherapy, which persisted when adjusting for age and comorbidities.
However, in the United States, doxorubicin/cyclophosphamide (AC) is favored over FEC despite no data comparing neoadjuvant AC-THP with AC-TH or TCHP. Here we report outcomes for patients with localized HER2+ breast cancer treated with pertuzumab-containing neoadjuvant regimens and AC-TH.
